Danaher Corporation (NYSE:DHR) Q4 2025 Earnings Call Transcript January 28, 2026Danaher Corporation beats earnings expectations. Academic and government demand remained muted but was stable sequentially, while clinical and applied end markets continued to perform well. Now let’s take a closer look at our fourth-quarter results across the portfolio and give you some color on our end markets today. Looking across end markets, we continue to see a modest recovery in Pharma, particularly in Europe, while biotech demand remained stable. If we do better from a core growth perspective, then 30% to 4%, there’s probably likely some upside here to EPS.